ArticleEJHaem2022

CB-103: A novel CSL-NICD inhibitor for the treatment of NOTCH-driven T-cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T-ALL.

Michael Medinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.